Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial.

@article{Costa2012ProceduralAE,
  title={Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial.},
  author={Ricardo Filipe Alves Costa and Alexandre S Abizaid and Andrea Claudia Le{\~a}o de Souza Abizaid and Bruno Garc{\'i}a del Blanco and Jacques Berland and Ivo Petrov and Philippe Brenot and Robert-Jan van Guens and Thierry Royer and Paolo Rubino and Maciej Lesiak and Jean Fajadet},
  journal={EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology},
  year={2012},
  volume={7 11},
  pages={1301-9}
}
AIMS To demonstrate the acute and early outcomes of the novel Nile PAX dedicated polymer-free paclitaxel-coated stents (Minvasys SAS, Gennevilliers, France) in the treatment of de novo coronary bifurcation lesions. METHODS AND RESULTS The Nile PAX device incorporates a cobalt-chromium alloy with a side aperture in the mid-stent designed to optimise scaffold at the bifurcation carina and side branch (SB) ostium, while maintaining SB access during procedure. From December 2008 to February 2010… CONTINUE READING